BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that Cancer Treatment Centers of America (CTCA) at Southeastern Regional Medical Center has purchased a BSD-500 Hyperthermia System (BSD-500). CTCA Southeastern Regional Medical Center, located in the metropolitan Atlanta area, is a new 226,000-square-foot, all-digital hospital focused exclusively on treating cancer. CTCA Southeastern, which will open in August 2012, will provide the most innovative medical technologies available for cancer treatment ( http://www.cancercenter.com).
CTCA is a network of hospitals that provides an unprecedented level of care to cancer patients. More than two-thirds of the patients are expected to come from outside the state of Georgia. Being a for-profit organization allows CTCA to invest profits in state-of-the-art technology, and CTCA has purchased BSD's hyperthermia systems for all of its sites. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care."
"This will be the seventh BSD hyperthermia system purchased by CTCA, and we are excited to have another BSD system placed in these prestigious cancer care facilities," stated Harold Wolcott, BSD's President. “Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors. Hyperthermia is a non-invasive method of increasing tumor temperature to stimulate blood flow, increase oxygenation, and render tumor cells more sensitive to radiation. By adding hyperthermia to radiation therapy, physicians can increase local tumor control in certain tumors while minimizing damage to healthy tissue."
About the BSD-500 Hyperthermia SystemThe BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors.